5-Fluorouracil and dihydropyrimidine dehydrogenase

被引：42
作者：
Tetsuro Kubota
机构：
[1] Department of Surgery, School of Medicine, Keio University, Tokyo 160-8582, 35 Shinanomachi, Shinjuku-ku
来源：
International Journal of Clinical Oncology | 2003年 / 8卷 / 3期
关键词：
5-Fluorouracil; Dihydropyrimidine dehydrogenase (DPD); DPD-inhibitory fluoropyrimidines (DIFs);
D O I：
10.1007/s10147-003-0319-7
中图分类号：
学科分类号：
摘要：
Dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme of (fluorinated) pyrimidine degradation that plays a significant role in the pharmacokinetics of 5-fluorouracil (5-FU). In addition, a catabolite of 5-FU induces a certain toxicity, and the sensitivity of 5-FU is determined by DPD activity in tumors. DPD is thus important clinically. Drugs have been developed that control variations of the pharmacokinetics of 5-FU by controlling or inhibiting DPD, thereby reducing toxicity and improving sensitivity. These fluorinated pyrimidines with DPD-inhibiting activity, called DPD-inhibitory fluoropyrimidines, contribute to oral therapy with 5-FU for cancer. This paper summarizes the important role of DPD in cancer chemotherapy with 5-FU.
引用
收藏
页码：127 / 131
页数：4
相关论文
共 58 条
[1]  
Heidelberger C., Chaudhuri N.K., Danenberg P., Et al., Fluorinated pyrimidines, a new class of tumor-inhibitory compounds, Nature, 179, pp. 663-666, (1957)
[2]  
Liu G., Franssen E., Fitch M.I., Et al., Patient preference for oral versus intravenous palliative chemotherapy, J Clin Oncol, 15, pp. 110-115, (1997)
[3]  
Sobrero A., Kerr D., Glimelinus B., Et al., New directions in the treatment of colorectal cancer: A look to the future, Eur J Cancer, 36, pp. 559-565, (2000)
[4]  
Diasio R.B., Clinical implications of dihydropyrimidine dehydrogenase inhibition, Oncology, 13, SUPPL. 3, pp. 17-21, (1999)
[5]  
Hoff P.M., Pazdur R., Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: A novel class of oral antineoplastic agents, Semin Oncol, 26, SUPPL. 18, pp. 52-56, (1999)
[6]  
Diasio R.B., Harris B.E., Clinical pharmacology of 5-fluorouracil, Clin Pharmacokinet, 16, pp. 215-237, (1989)
[7]  
Naguib F.N.M., El Kouni M.H., Cha S., Enzymes of uracil catabolism in normal and neoplastic human tissues, Cancer Res, 45, pp. 5405-5412, (1985)
[8]  
Ho D.H., Townsend L., Luna M.A., Et al., Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate, Anticancer Res, 6, pp. 781-784, (1986)
[9]  
Aboagye E.O., Saleem A., Cunningham V.J., Et al., Extraction of 5-fluorouracil by tumor and liver: A noninvasive positron emission tomography study of patients with gastrointestinal cancer, Cancer Res, 61, pp. 4937-4941, (2001)
[10]  
Chazal M., Etienne M.C., Renee N., Et al., Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver, Clin Cancer Res, 2, pp. 507-510, (1996)
123456